Saturday 17 October 2026 Export ANRO’s income statement to Excel — free account

Alto Neuroscience, Inc.

In the quarter to June 2026, EPS was flat, free cash flow fell 43.4% and total debt fell 15.7%, each against the same quarter a year earlier.

22.07 0.55 −2.43%

Follow ANRO

Alert me

Market cap: $887.7M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 3.57

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	1	—

Insider Ownership 16.96%

Capital & Financial Ratios $m

Market Cap 887.66

Revenue —

Net Income (84.24)

Free Cash Flow (68.84)

Net Debt (225.08)

Current Ratio 14.85

Debt/Equity 0.09

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 4.31

Past 5Y EPS Growth —

This Y EPS Growth (27.14%)

Next Y EPS Growth (10.23%)

Next Y revenue growth —

Next 5Y EPS Growth (11.71%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	83	168	176	244
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	85	169	178	247

	2023	2024	2025	Q'26
Payables	1	2	2	4
ST’ Debt	—	—	1	4
Other	—	—	—	—
	6	10	11	17

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	—	0.00%
Earnings	—	—	0.00%
Book Value	—	—	64.70%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(27)	(20)	—	—	—
’25	(17)	(14)	(10)	(12)	(52)
’24	(11)	(12)	(12)	(13)	(47)
’23	(8)	(7)	(8)	(12)	(33)
’22	—	—	—	(20)	(20)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(28)	(20)	—	—	—
’25	(17)	(14)	(10)	(12)	(52)
’24	(11)	(12)	(13)	(14)	(49)
’23	(8)	(7)	(8)	(12)	(34)
’22	—	—	—	(21)	(21)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.80)	(0.65)	—	—	—
’25	(0.56)	(0.65)	(0.52)	(0.45)	(2.19)
’24	(0.76)	(0.60)	(0.62)	(0.56)	(2.50)
’23	(1.97)	(2.33)	(2.44)	(2.98)	(9.73)
’22	—	—	—	—	(8.04)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	—	—	—	3.56	1.60	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	—	—	—	24.00	20.91
People
People	Employees	—	—	—	—	—	—	63	63	76	68
	Revenue/emp, $m	—	—	—	—	—	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	0	—	—	—	—
	Gross margin, %	—	—	—	—	—	100.00	—	—	—	—
	EBT	—	—	—	—	—	(9)	(28)	(36)	(61)	(63)
	EBT margin, %	—	—	—	—	—	(4,374.76)	0.00	0.00	0.00	0.00
	Net income	—	—	—	—	—	(9)	(28)	(36)	(61)	(63)
	Depreciation	—	—	—	—	—	0	0	0	1	1
Per share, $
Per share, $	Revenue	—	—	—	—	—	0.09	0.00	0.00	0.00	0.00
	Earnings	—	—	—	—	—	(3.81)	(8.04)	(9.73)	(2.50)	(2.19)
	Cash flow	—	—	—	—	—	(3.84)	(5.92)	(8.96)	(1.93)	(1.79)
	Capex	—	—	—	—	—	(0.28)	(0.21)	(0.13)	(0.08)	0.00
	Free cash flow	—	—	—	—	—	(4.12)	(6.13)	(9.09)	(2.01)	(1.80)
	Book value	—	—	—	—	—	10.64	9.82	18.71	6.16	5.24
	Shares, m	—	—	—	—	—	2	3	4	25	29
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	0.00	—	—	—	—
	P/S	—	—	—	—	—	0.00	—	—	—	—
	P/B	—	—	—	—	—	0.00	—	—	—	—
	EV/Sales	—	—	—	—	—	0.00	—	—	—	—
	EV/FCF	—	—	—	—	—	(0.13)	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	—	—	—	—	—	(9)	(20)	(33)	(47)	(52)
	Capex	—	—	—	—	—	(1)	(1)	0	(2)	0
	Free cash flow	—	—	—	—	—	(10)	(21)	(34)	(49)	(52)
Balance, $m
Balance, $m	Working capital	—	—	—	—	—	26	44	80	159	166
	Total debt	—	—	—	—	—	—	9	10	12	19
	Net debt	—	—	—	—	—	(26)	(39)	(73)	(157)	(157)
	Shareholders’ equity	—	—	—	—	—	26	34	70	151	151
Returns, %
Returns, %	ROA	—	—	—	—	—	0.00	(69.58)	(52.81)	(46.51)	(34.92)
	ROIC	—	—	—	—	—	0.00	0.00	0.00	0.00	0.00
	ROE	—	—	—	—	—	0.00	108.91	65.96	(153.99)	(41.80)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2021

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CGEM Cullinan Therapeutics, Inc.	$901.0M	— (loss-making)	4.8×	—	n/m	+33.66% (above 0%: growing)	100.00%	0.00%	Compare
AKTS Aktis Oncology, Inc.	$890.5M	— (loss-making)	— (loss-making)	—	n/m	−12.77% (below 0%: shrinking)	100.00%	(853.99%)	Compare
ANRO Alto Neuroscience, Inc.	$887.7M	— (loss-making)	—	—	n/m	−43.41% (below 0%: shrinking)	—	0.00%
RIGL Rigel Pharmaceuticals, Inc.	$882.6M	2.6×	7.9×	−22.60% (below 0%: shrinking)	−72.07% (below 0%: shrinking)	−229.99% (below 0%: shrinking)	89.17%	29.95%	Compare
JBIO Jade Biosciences, Inc.	$875.1M	— (loss-making)	—	—	n/m	−115.11% (below 0%: shrinking)	0.00%	0.00%	Compare
MLTX MoonLake Immunotherapeutics	$873.2M	— (loss-making)	—	—	n/m	−1.89% (below 0%: shrinking)	0.00%	0.00%	Compare
GLUE Monte Rosa Therapeutics, Inc.	$863.4M	— (loss-making)	— (loss-making)	−61.33% (below 0%: shrinking)	n/m	−34.11% (below 0%: shrinking)	100.00%	(547.84%)	Compare
KURA Kura Oncology, Inc.	$862.9M	— (loss-making)	— (loss-making)	+36.54% (above 0%: growing)	n/m	−109.05% (below 0%: shrinking)	98.84%	(349.77%)	Compare
ALMS Alumis Inc.	$842.4M	— (loss-making)	— (loss-making)	−37.66% (below 0%: shrinking)	n/m	+23.59% (above 0%: growing)	100.00%	(8,956.38%)	Compare
Median of peers	$874.1M	—	—	−30.13%	—	−23.44%	99.42%	(174.88%)

All 614 Biotechnology stocks →

Alto Neuroscience, Inc. (ANRO) key facts

Alto Neuroscience, Inc. (ANRO) is a Biotechnology company in the Healthcare sector, listed on the New York Stock Exchange.
As of October 16, 2026, ANRO traded at $22.07, a market capitalization of $887.7 million.
Return on equity was −41.8% and debt-to-equity 0.09.

Source: company filings (standardised) and stockrow calculations.